Azitra Stock Soars 41.5% on $20M Funding Deal

Azitra's stock surged 41.5% in pre-market trading on April 25, 2025, driven by a significant funding deal.

Azitra has entered into a share purchase agreement with Alumni Capital LP, securing up to $20 million in funding over a 20-month period. This agreement allows Azitra to sell common stock and warrants, providing the necessary capital to advance its clinical pipeline, particularly in the field of rare diseases and dermatology treatments.

The funding deal is expected to bolster Azitra's financial position, enabling the company to accelerate its research and development efforts. This strategic partnership with Alumni Capital is seen as a positive move, as it provides a stable funding source and reduces the need for immediate dilution of shares.

Investors have responded positively to the news, with the stock price reflecting the market's confidence in Azitra's future prospects. The funding will support the company's ongoing clinical trials and potentially lead to new treatment options for patients suffering from rare diseases and dermatological conditions.